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Abstract 
ERα recruits co-activator and transcription factors to the Estrogen 
Responsive Elements (EREs) to induce transcription. Co-activator complexes 
facilitate transcriptional activation in part by interacting with chromatin 
remodeling and histone-modifying enzymes, which render the target chromatin 
permissive to transcriptional activation. One important protein is LSD1 or 
KDM1, a flavin adenine dinucleotide-dependent amine oxidase, that catalyzes 
the removal of methyl groups from di-methylated lysine 4 and lysine 9 in H3 
histone, H3K4m2 and H3K9m2, to repress or induce transcription, 
respectively.   
The scope of this study is to determine whether cAMP and protein 
kinase A (PKA) regulate LSD1 and the initiation transcription complex 
formation.  
Our data demonstrate that cAMP-PKA phosphorylate LSD1 in 
threonine 110 and stimulate the interaction with active estrogen receptor α. 
This event is crucial for the assembly of the transcription initiation complex. 
We have mapped the region in the receptor necessary for this interaction and 
we have generated a mutant LSD1 that is not able to interact with the receptor 
and to stimulate estrogen-dependent transcription. PKA phosphorylates LSD1 
at the mapped site (threonine 110) in vitro, and favors the recruitment of 
factors required for the transcription initiation complex formation.  
These data illustrate the interplay between two major signaling 
pathways, estrogens and cAMP-PKA, and how they regulate transcription 
initiation induced by estrogens. 
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Chromatin structure and regulation. 
In the eukaryotic cells, the genetic information is packaged into a 
nuclear structure called chromatin that was first identified by Walther 
Flemming in 1882 (Flemming W., 1882). Chromatin is the tightly association 
between negatively charged DNA and positively charge histone proteins. The 
complex is defined nucleosome and consists of 146 base pairs (bp) of DNA 
wrapped in 1.75 turns around a histone octamer, all of which is organized as a 
central tetramer of H3/H4 histones surrounded by two histone H2A/H2B 
dimers (Figure 1). The DNA between nucleosomes is associated with the 
histone H1 to obtain the high-order compression of the chromatin. This 
classical view of 
chromatin as a simple 
structural entity has 
recently been superseded 
by evidences 
demonstrating that 
nucleosome deposition, 
subunit composition, and 
post-translational 
modification can 
profoundly affect how 
chromatin function is regulated. Chromatin conformations can be defined as: 
“euchromatin”, with a low degree of compression associated with a relaxed 
conformation that allows to recognize DNA and regulate transcription by 
transcription factors (Agalioti T. et al., 2000), and “heterochromatin”, with a 
high degree of compression that can be susceptible to changes in the degree of 
compression, which is observed during the phases of cell cycle. Epigenetics 
controls the variations in the structure or the degree of chromatin compression 
facilitating or preventing access of the transcription factors required for gene 
expression processes. This kind of regulation occurs via mechanisms that 
involve DNA methylation and oxidation; and post-translational modification of 
the N-terminal tails of histone proteins such as methylation, demethylation, 
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acetylation, deacetylation, biotinylation, 
ubiquitination, and sumoylation and 
phosphorylation (Figure 2). Each of 
these modifications has a characteristic 
effect on the level of gene expression: 
the addition of acetyl groups to the 
histones is frequently related to 
transcriptional activation; the 
methylation-demethylation can be 
associated with transcriptional activation or repression depending on the 
function of the residue and the degree of methylation (Berger S. L. 2007; 
Latham J. A. and Dent S.Y. 2007). These modifications play a key role in 
regulating transcription, contributing to epigenetic memory, and maintaining 
genome integrity.  
 
Histone Methylation. 
Histone methylation occurs at the 3-amino group of lysine (K) and the 
guanidine group of arginine (R) and is catalyzed by enzymes that use S-
adenosyl-L-methionine (SAM) as the methyl group donor (Paik W. K. and 
Kim S., 1971). Histones contain numerous lysine and arginine residues, many 
of which being methylated in vivo (Zhang Y and Reinberg D., 2001; 
Margueron R. et al., 2005). Histone methylation is considered as an important 
modification linked to both transcriptional activation and repression 
(Margueron R. et al., 2005). Histone methylations of arginine can occur on 
H3R2, R8, R17 and R26 and H4R3 and can active or repress transcription. 
Histones H4K20, H3K4, -9, -27, -36, and -79 were studied extensively and 
linked to transcriptional regulation and DNA damage response (Margueron R. 
et al., 2005; Martin C. and Zhang Y., 2005). Lysines can be mono-, di-, and tri-
methylated (Bannister A. J. and Kouzarides T., 2004), whereas arginines can 
be both mono-methylated and dimethylated in asymmetrical or symmetrical 
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manner (Bedford M. T. and Richard S., 2005). In general, methylation at 
histone H3K4 and H3K36, including di- and trimethylation at these sites, has 
been linked to actively transcribed genes (Martin and Zhang, 2005). For the 
methylation at H3K9 there are different point of view: although the H3K9 
methylation is considered a repressive mark for euchromatic genes (Nielsen S. 
J. et al., 2001), the H3K9 trimethylation (H3K9Me3) is shown associated with 
actively transcribed genes (Vakoc C. R. et al., 2005). All these differentially 
methylated lysine residues may serve as docking sites for different effector 
proteins and/or platforms for chromatin modifiers that perform “writer” and 
“reader” functions and act in a spatially and temporarily coordinated manner 
(Ruthenburg A. J. et al. 2007; Taverna S. D. et al. 2007). “Writers” usually 
have subunits harboring catalytic activity that add or remove marks on 
histones, while “Readers” often are characterized by domains that specifically 
recognize and bind to these marks (Ruthenburg A. J. et al. 2007). These 
chromatin-regulating complexes include histone acetyltransferases (HATs), 
DNA methyltransferases (DNMTs), histone deacetylases (HDACs), histone 
methyl-transferases (HMTs) and histone demethylases (HDMs) that act in a 
stepwise and/or combinatorial manner and engage in extensive cross talk. 
Lysine Specific Demethylase: LSD1 or KDM1 
In the last ten years with the development of new technologies for the 
analysis of the histone methylation pattern, the hypothesis that the link between 
cellular phenotypes and methylation-demethylation pattern is part of “normal” 
cell development and/or insurgence of different pathologies, such as cancers is 
making its way. Until 2004 histone methylation was considered a stable and 
irreversible mark of chromatin. In that year, the description of the action 
mechanism of the first enzyme endowed with lysine specific demethylase 
activity, opened new research outlook on these proteins and their association 
with epigenetic regulatory mechanisms, breaking the paradigm of irreversible 
methylation (Shi Y. et al., 2004).  
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LSD1/KDM1A (below named LSD1) is the first histone demethylase 
characterized, a nuclear amine oxidase as part of a multiprotein corepressor 
complex that contains both histone deacetylase-1 or -2 and demethylase 
activities (Shi Y. et al., 2004).  
LSD1 consists of three major domains: an N-terminal SWIRM (Swi3p/ 
Rsc8p/Moira) domain (Yoneyama M. et al., 2007), a C-terminal AOL (amine 
oxidase-like) domain, and a central protruding Tower domain (Stavropoulos P. 
et al., 2006). 
The C-terminal domain has high sequence homology to FAD-dependent 
polyamine oxidases family (Da G. et al., 2006; Qian C. et al., 2005). The AOL 
domain of LSD1 contains two sub-domains, a FAD-binding sub-domain and a 
substrate-binding sub-domain (Figure 3A). The interface of the two sub-
domains forms a large cavity, in which catalytic center is localized. The N-
terminal SWIRM domain reveals a compact helix-turn-helix-related fold found 
in several chromatin-associated proteins (Qian C. et al., 2005). Although some 
studies reveal that the SWIRM domains bind and anchor DNA and present 
their associated protein or protein complexes to nucleosomal substrates, the 
precise function of the LSD1 SWIRM domain is still unknown (Yoneyama M. 
et al., 2007). Additionally, the LSD1 SWIRM domain makes close interactions 
with the amine oxidase domain, forming a highly conserved cleft, that serve as 
an additional site to bind histones (Metzger E. et al., 2005). The Tower domain 
forms a long helix-turn-helix structure, into the AOL domain, and offers a 
surface for the interaction to protein co-repressor element silencing factor 
CoREST (Figure 3 B). CoREST binds LSD1 and modulates its activity. 
Biochemical studies have demonstrated that the demethylase activity of LSD1 
on H3K4 is regulated by the association with CoREST (Lee M. G. et al., 2005). 
The C-terminal region of CoREST, which contains the SANT2 domain, 
confers to LSD1 the ability to demethylate nucleosomal substrates. Moreover, 
the co-crystal structure of the LSD1-CoREST complex displays that the region 
between the SANT1 and the SANT2 domains, in the C-terminal region of 
CoREST, sorrounds the LSD1 Tower domain with the SANT2 domain resting 
on the tip of the tower (Yang M. et al., 2006). The overall structure appears as 
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anchor to lock the complex into the nucleosomal surface. The main and well-
characterized function of LSD1 is the catalyzation of the histone H3-Lys4 
mono- and di-methylation (Forneris F. et al., 2005), even though after 
androgen stimulation the activity of LSD1 on H3K9 has also been reported 
(Metzger E. et al., 2005) (Figure 3C). 
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Histone demethylase role in development and stem cell function. 
 
LSD1 is considered to play cardinal functions in the formation and 
development of organs and tissues such as heart, brain and skeletal muscle. Its 
essential role in cellular energy expenditure, inflammatory responses and 
hematopoiesis is described. In human LSD1 is encoded by a single gene, 
KDM1A, located at the chromosome 1 p36.12. Conditional knockout of LSD1 
in embryonic stem (ES) cells causes embryonic lethality at approximately day 
6 (Foster C. T. et al., 2010). Mice embryos, in which the LSD1 expression is 
absent, have dimensions reduced compared to heterozygous controls 
suggesting a block to development shortly after implantation. The aberrant 
developmental program in these mice leads to embryonic lethality. LSD1 
knockdown by shRNA, in human ES cells, causes a partial cell arrest in the 
G0/G1 phase with decreased growth rate and up-regulation of genes involved 
in the development processes such as FOXA2 (forkhead box A2), EOMES 
(eomesodermin), BMP2 (bone morphogenetic protein 2) and SOX17 (Adamo 
A. et al., 2011). LSD1 orthologs in Drosophila melanogaster and 
Caenorhabdis elegans are expressed in the germline. Inactivation of the 
Drosophila melanogaster ortholog of LSD1, Su(var)3–3 (suppressor of 
variegation 3–3), leads to a global reduction of H3K4me2/me1 and H3K9me 
levels in heterochromatic regions that could be the reason of sterility and tissue 
defects. The Caenorhabdis elegans SPR-5 (suppressor of presenilin defect) 
protein has also been implicated in the control of H3K4me2 levels in the 
germline, in fact increased levels of H3K4me2 are observed only in late 
generations, corroborating the ideas that LSD1 orthologs regulates the genes 
expression during spermatogenesis (reviewed in Amente S. et al., 2013). 
Together, these observations suggest a central role for H3K9 demethylation 
activity of LSD1 in the early development and maintaining stem cell function. 
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Histone demethylation leads to DNA oxidation 
 
LSD1 belongs to flavin-dependent amine oxidase family that typically 
catalyzes the oxidation of an amine-containing substrate using molecular 
oxygen as the electron acceptor (Binda C. et al., 2002; Shi Y. et al., 2004; 
Forneris F. et al., 2005). The amino group of the methylated Lys is oxidized, 
this generates the corresponding imine compound, which is subsequently 
hydrolyzed, the final product is formaldehyde. The oxidation reaction leads to 
the reduction of the two-electron hold in protein-bound FAD cofactor, which is 
regenerated to its oxidized form by molecular oxygen to produce hydrogen 
peroxide.  
Recently, Perillo et al. have shown that H2O2 produced during LSD1 mediated 
demethylation at estrogen receptor (ER) target genes results in production of 8- 
oxo-guanine lesions. This DNA damage event mediates the recruitment of the 
8-oxo-guanine DNA glycosylase-1 (OGG1) and topoisomerase IIb repair 
enzymes at the regulatory regions of the gene. Interestingly, the single stranded 
breaks induced during the DNA repair process is required for estrogen-
dependent genes transcription because may facilitate DNA bending permitting 
more efficient RNA Pol II loading onto the promoter during gene activation 
(Perillo B. et al., 2008) (Figure 4). 
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LSD1 is a transcriptional co-repressor or co-activator? 
 
A key issue is to define the biological properties of LSD1, especially in 
relation to its ability to induce or repress the gene transcription. First of all, 
LSD1 is a cofactor of several molecular complexes, including CoREST and 
NuRD, acting as co-repressor, and consistent with this role in transcription 
repression, LSD1 demethylates monomethyl and dimethyl histone H3 lysine 4 
(H3K4me1 and H3K4me2). Secondly, LSD1 was described with androgen 
(AR) or estrogen (ER) nuclear receptors acting as co-activator (Shi Y. et al., 
200). During androgen receptor (AR)-activated gene expression, LSD1 
removes mono- and dimethyl marks from H3K4me1/me2 to H3K9me1/ 
(Gargia-Basserts 
I. et al., 2007), 
promoting gene 
transcription 
(Figure 5). The 
key mechanisms 
that control this 
dual specificity 
of demethylation 
is the phosphorylation of histone H3 at threonine 6 (H3T6) by protein kinase C 
beta I that inhibit LSD1 demethylating H3K4 during AR-dependent gene 
activation. Moreover, after androgen treatment, protein kinase C is recruited to 
AR target promoters and phosphorylates H3T6. This modification switches 
LSD1 H3K4 demethylating activity from H3K4me2 to H3K9me1 and 
H3K9me2 (Imhof A. et al., 2010).  
In addition, LSD1 is a chromatin-modifying enzyme, which serves as a 
docking module for the stabilization of the associated corepressor complexes 
on chromatin and is finely tuned and highly specific. Although the Lys4 is the 
main site of LSD1 oxidative action, the enzyme is also sensible to covalent 
modifications on neighboring residues. The histone modifications, in fact, are 
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important signature for the activity of LSD1. Lys9 acetylation affects enzyme 
catalysis, whereas phosphorylation of Ser10 totally abolishes its activity. LSD1 
does not have a strong preference for mono- or dimethylated H3K4, it binds H3 
independently of Lys4 methylation. The fact that LSD1 acts with similar 
efficiency on mono- and dimethylated substrates indicates that in vivo it works 
resetting H3K4 to its demethylated state.  
 The cascades of events that lead to transcriptional activation/repression should 
be: 
- Phosphorylation/Dephosphorylation of Ser10 by a Kinase/phosphatase; 
- Lys9 deacetylation by HDAC1/2; 
- H3 demethylation catalyzed by LSD1 (reviewed by Forneris F. et al., 
2005).  
 
 Role of transcription factors in LSD1 gene-recruitment  
The regulation of gene expression within euchromatin requires the delivery 
of chromatin-modifying enzymes by DNA-bound transcription factors. 
Following a stimulus, transcription factors bind to their gene-promoter regions 
and induce a cascade of modification events that result in the expression or 
silencing of the gene. Nuclear receptors regulated transcription by binding 
ligands to the C-terminal domain, this causes conformational changes, that 
include a change in the position of the so-called AF2 helix. The shift of AF2 
helix favors the nuclear receptor association with specific coactivator 
complexes, converting of the receptor into a transcription activator (reviewed 
in Rosenfeld et al., 2006). Thus, when nuclear receptors, such as the thyroid 
hormone (T3) and the retinoid acid (RA) receptors, lack of ligand, act as 
repressors recruiting specific corepressor complexes via the “CoRNR” domain 
(Horlein et al., 1995; Chen J. D. and Evans R. M., 1995; Heinzel T. et al., 
1997), whereas, in the presence of ligand, they are functionally converted to 
activators by recruiting coactivator complexes. Nowadays there are many 
evidences that linked between LSD1 and the ERa-mediated gene activation 
program. One of these are the discovery that approximately 58% of ERa+ 
promoters also exhibiting LSD1 recruitment. The 80% of the 4200 LSD1-
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positive promoters were associated with RNA polymerase II and gene 
activation (Garcia-Bassets I et al., 2007). Recently it is shown that LSD1 is an 
essential mediator of the interchromosomal interactions necessary for E2-
dependent ERα-mediated transcription (Hu Q. et al., 2008). In particular, Julie 
A. Pollock et al. have elucidate that the physical presence of LSD1 both as a 
scaffolding protein, and its demethylase enzymatic activity on the ERE region, 
was important for ERα-regulated transcription, in fact E2 treatment induces the 
recruitment of ERα and LSD1 to ERE of pS2, and influences the methylation 
status of histones at or close to the pS2 EREs (Pollock J. A. et al., 2012). 
Therefore, it is of particular interest to further explore the linkage between the 
recruitment of nuclear receptors and the coregulatory complexes that underlie 
ligand-dependent activation of transcriptional programs. 
 
Estrogen receptors: “genomic” and “non-genomic” actions. 
 
Steroid hormones, such as 17β-estradiol (E2), play pivotal roles in the 
regulation of sexual development and fertility in both males and females 
(Couse J. F. and Korach K. S., 1999; Nef S. and Parada L. F., 2000). Estrogens 
also regulate metabolic processes in fat, liver, and bone tissues (DeCherney A., 
1993; Vaananen H. K. and Harkonen P. L., 1996). In addition, estrogens, not 
only influence different disease states, for example, cancers (e.g., breast, 
uterine) causing hormone-dependent growth and proliferation (Foster K.R., 
Ratnieks F. L., 2001; Prall O. W. et al., 1998), but also important 
physiological/pathological processes, such as inflammation, cellular 
differentiation, cardiovascular integrity and immunity. Estrogen elicits their 
actions through ER proteins. ERs exist as two isoforms, ERα and ERβ, with 
different functions and tissue expressions, they are members of a conserved 
superfamily of nuclear receptors that have the same conservative structure 
(Mangelsdorf D. J. et al., 1995).  
ERα, like the other nuclear receptors, contains two C4-type zinc fingers 
and binds as a dimer to palindromic sequences known as estrogen response 
elements (ERE) (Schwabe J. W. R. et al., 1993). The ligand-binding domain 
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(LBD) is encoded within a region of about 300 amino acids and is bound by 
estrogens and anti-estrogens (Tanenbaum D. M. et al., 1998). The LBD also 
contains a ligand-activated transcription activation function, AF-2, as well as 
sequences required for ligand-dependent dimerization. The N-terminal 180 
amino acids contain transcription activation function AF-1. Extensive studies 
have shown that AF-1 and AF-2 can act both independently and synergistically 
in a promoter- and cell-specific manner (Tsai M. J. and O’Malley B. W., 
1994). A large number of studies have described the mechanisms underlying 
the inhibition of ERα activity by partial anti-estrogens such as tamoxifen and 
pure antagonists such as ICI 182, 780. These studies have shown that the 
activity of tamoxifen results in the inhibition of AF-2, whereas ICI 182, 780 
prevents the activation both AF-1 and AF-2, increasing its turnover and 
causing the disruption of the estrogen receptor nucleo-cytoplasmic shuttling 
(Dauvois S. et al., 1992; Dauvois S. 
et al., 1993). 
Mutational analysis and 
crystallographic studies have 
defined a region at the C-terminus 
of the ERα, LBD, originally 
referred to as AF-2 activating helix (AH) and now known to form part of an 
amphipathic helix, helix 12, of the LBD, which is essential for ligand-
dependent transcriptional activity. Ligand binding results in the realignment of 
helix 12, inducing co-regulators to associate (Figure 6). Determination of the 
LBD structures for a number of other nuclear receptors indicates that ligand-
induced H12 realignment is a common feature of the nuclear receptor LBD 
(Moras D. and Gronemeyer H., 1998).  
The “genomic” pathway of estrogen consists in the activation of 
estrogen receptors after hormone stimulation; ERs dissociate from nuclear 
chaperone proteins, dimerize, and bind to DNA at specific sequences known as 
estrogen response elements (EREs), modulating the estrogen-dependent 
transcription of responsive genes (Deroo B. J. and Korach K. S., 2006).  
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In addition to the “genomic” pathway, it is recently described an 
alternative mechanism of action, “non-genomic”, that is faster that the genomic 
one, and by which estrogen control the cell cycle progression, cell survival and 
cell migration. Some of these effects are mediated by estrogen receptors, but 
most of them are dependent by the activation of cellular kinases, that are the 
proto-oncogenic tyrosine-kinase (Src), the phosphatidylinositol-3-kinase 
(PI3K), the mitogenic protein kinase (MAPK), the protein kinase A  (PKA) and 
C (PKC) through G protein-coupled receptors (GPCRs) or ionic channel 
(Castoria G. et al., 2008). All these signaling pathways culminate, depending 
on the cell context, in differentiated effects of steroid hormones, such as 
proliferation, survival, migration and differentiation, through the activation of 
several gene expression programs (Figure 7).  
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cAMP/PKA signaling pathway 
 
The cyclic adenosine monophosphate (cAMP) is an important 
intracellular signaling molecule, which acting as second messengers between 
extracellular stimuli such as hormones, elicits intracellular response. While the 
specific function of a given signal varies according to the cell type and the 
extracellular environment, stimulus activating the signal, generally activates 
the cyclase enzyme with the formation of the cyclic nucleotide (cNT). This, in 
turn affects the activity of downstream effectors including kinases, ion 
channels, transcription factors, and scaffolding proteins. Among these, PKA 
play an important role in different cellular processes, for example negative 
regulator of cAMP signaling, mediator of anti-apoptotic and pro-apoptotic 
cascades, etc. etc. (Rehmann, H. et al., 2007; Insel, P. A. et al., 2012). 
The holoenzyme, PKA, is a tetramer consisting of two regulatory 
subunits (R) and two catalytic subunits (C): the formers contain two binding 
sites for cAMP, and upon its binding, the latters activate their substrates by 
phosphorylation (Gerits, N. et al., 2008). The catalytic activity of the C subunit 
is decreased by a protein kinase inhibitor (PKI) that can also acts as a 
chaperone and promotes nuclear export of the C subunit, decreasing nuclear 
functions of PKA. PKA-anchoring proteins (AKAPs) provide specificity in 
cAMP signal transduction by making closer interaction between PKA, specific 
effectors and substrates. They can also target PKA to particular subcellular 
locations and anchor it to ACs (for immediate local activation of PKA) or 
PDEs (to create local negative feedback loops for signal termination) (Wong 
and Scott 2004). A large number of cytosolic and nuclear proteins have been 
identified as substrates for PKA (Tasken et al., 1997). PKA phosphorylates 
numerous metabolic enzymes, such as glycogen synthase and phosphorylase 
kinase that inhibits glycogen synthesis and promotes glycogenolysis. It can 
phosphorylate also acetyl CoA carboxylase, which inhibits lipid synthesis. 
PKA regulates other signaling pathways too. For example, it inactivates 
phospholipase C (PLC) b2, while it activates MAP kinases through 
phosphorylation respectively. The activities of Raf and Rho can be decreased 
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PKA too, and it modulates ion channel permeability. In addition, it regulates 
the expression and activity of various ACs and PDEs, modulating itself its 
activity. PKA transcription regulation is mainly got to the direct 
phosphorylation of the transcription factors cAMP-response element-binding 
protein (CREB) and cAMP-responsive modulator (CREM) (Rehmann H. et al., 
2007).  Phosphorylation allows these proteins, once activated, to interact with 
the transcriptional coactivators CREB-binding protein (CBP) and p300 when 
bound to cAMP-
response elements 
(CREs) of target 
genes (Mayr B. and 
Montminy M., 
2001). The CREM 
gene encodes the 
cAMP-induced 
transcription 
repressor ICER, 
which makes a 
negative feedback 
on itself (Sassone-
Corsi P., 1995). 
PKA can also 
influence the 
activity of other 
transcription 
factors, including some nuclear receptors (Figure 8). 
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Interplay between estrogen and cAMP/PKA transduction pathways 
in transcription factors activation 
At this time it is evident that estradiol increases the intracellular cAMP 
levels both “in vitro” and “in vivo” (Szego C. and Davis J., 1967; Nakhla A. 
et al., 1994). It in turn induces adenylyl cyclase activation and stimulates 
cAMP response element (CRE)-mediated gene expression (Aronica S. M. et 
al., 1994). There is data that report a nonclassical effect of estrogen on the 
expression of different types of genes through cAMP-mediated mechanisms 
(Szego E’va M. et al., 2006; Hously M. D. Kolch W., 2000; Liu D. et al., 2009) 
Steroid hormones exert dramatic effects on neuronal expression of genes; in 
fact promote transcription of neurotensin/neuromedin (NT/N) by interactions 
with the cAMP cascade in a neuronal cell line, SK-N-SH, and in a mouse 
model (Watters J. J. and Dorsa D. M., 1998). Furthermore, cAMP/PKA 
signaling increases estrogen relate receptor α phosphorylation and nuclear 
localization, recruitment to the SP-A promoter, and interaction with PKAcat 
and SRC-2, resulting in the up-regulation of SP-A gene transcription (Liu D. et 
al., 2009).  
Moreover, cAMP is involved in resistance to steroid antagonists through the 
activation of the steroid receptor coactivator-1 (SRC-1) (Bai W. et al., 1997; 
Rowan B. G. and O' Malley B. W. 2000).  
All these observations highlight a role for cAMP/PKA-dependent pathway in 
the estradiol regulation of transcription. This “cross-talk” may represent a more 
generalized mechanism by which steroid hormones act through other signal 
transduction cascades to regulate the gene expression.  
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Aim of the study  
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Estrogens play important roles in the regulation of sexual development, 
fertility, metabolic processes and disease states. The biological effects of 
estrogens are mediated by the interaction with two intracellular estrogen 
receptors, ERα and ERβ. Upon interaction with ERs, estrogens induce a 
conformational change of the receptor, which favors receptor dimerization and 
recruitment to promoter elements either directly, through their DNA-binding 
domain or indirectly, through interaction with other transcription factors. ER 
complexes then recruit transcriptional co-regulators (co-activators and co-
repressors) to increase or inhibit target gene transcription. Many transcriptional 
co-regulators of nuclear receptors exhibit enzymatic activities that participate 
in their mechanism of action, such as acetyltransferases (HATs) or histone 
deacetylases (HDACs), and methyltransferases. All these enzymes may act as 
regulators of gene expression effecting post-translational modifications at the 
N-terminal tails of histones. 
Recently, LSD1 has been shown to play a role in transcription induced 
by androgens, estrogens or Myc (Metzger E. et al., 2005; Perillo B. et al. 2008; 
Amente S. et al., 2010). Mono aminoxidase activity of the enzyme is essential 
for the formation of the transcription initiation complex induced by androgens, 
estrogens and Myc. It is known that LSD1 demethylates selectively H3K4me2 
“in vitro”, while “in vivo” it binds the androgen or estrogen receptors and 
favors demethylation H3K9me2 (Shi Y. et al., 2004; Metzger E. et al., 2005). 
Notwithstanding, the mechanism by which the enzyme is recruited to the ERE 
sequences and activates the estrogen-dependent gene transcription, remains 
still elusive. Estrogens, through their non-genomic pathway, can activate many 
different signaling pathways, such as cAMP/PKA pathway, that in turn activate 
several gene transcription programs. During their transit from cytoplasm to 
nucleus, estrogen receptor genomic and the non-genomic actions converge in 
one or more points.  
Our aim is to study both “in vitro” and ”in vivo” the mechanism that 
regulates the recruitment of LSD1 to the ERE region following estrogen 
stimulation. We have focused our attention on the role cAMP/PKA-mediated 
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association of LSD1 with the transcriptional initiation complex and on the 
mechanism of induction of transcription of the estrogen-dependent genes.  
We wish to demonstrate that modification of LSD1 at a specific site on the N-
terminal domain facilitates the assembly of the transcription initiation complex 
driven by the estrogen receptor. We will analyze the recruitment of several co- 
factors, including the large subunit of RNA polymerase II, the single strand 
binding protein RPA, and the catalytic subunit of PKA.  
 We wish to identify the critical elements that regulate estrogen induction of 
transcription of target genes. 
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Materials and Methods 
 
Cell cultures, treatments and transfection 
 
Human breast cancer MCF-7 cells were grown at 37°C in 5% CO2 in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with phenol red, 
L-glutamine (2 mM), insulin (10 μg/ml), hydrocortisone (3.75 ng/ml), and 10% 
fetal bovine serum (FBS, Invitrogen, Rockville, MD, USA). Cells were 
provided with fresh medium every 3 days. To evaluate the effect of specific 
treatment challenge, cells were grown in phenol red-free DMEM containing 
10% dextran–charcoal-stripped FBS for 3 days, and then treated according to 
the experimental condition with 10 E2 (Sigma-Aldrich, Co., St. Louis, MO, 
USA), 1 µM ICI 182.780 (Sigma-Aldrich, Co., St. Louis, MO, USA), 10 µg/ml 
PKA inhibitor P9115 (PKI) (Sigma-Aldrich, Co., St. Louis, MO, USA), 10 µM 
H89 B1427 (Sigma-Aldrich, Co., St. Louis, MO, USA), 10 µg/ml PKC 
inhibitor (PKCi) (Chalbiochem), 100 µM 8-Br-cAMP (Sigma-Aldrich, Co., St. 
Louis, MO, USA), 40 µM Foskiln (Sigma-Aldrich, Co., St. Louis, MO, USA). 
To obtain LSD1 overexpression, MCF-7 cells were transiently transfected 
with plasmids carrying LSD1wt tagged with FLAG (p3xFLAG-pLSD1wt), or 
its T110A mutated form, LSD1-Ala (p3xFLAG-pAla) (Amente S. et al., 2010), 
using NeonR Transfection System (Life Technologies) with the following 
settings: 1100V, 30ms and 2 pulses.  
In all transfections, pEGFPC3 plasmid was included to determine and 
normalize transfection efficiency through FASC analyses. Experiments varying 
in the transfection efficiency above 20% were discarded. All data used derived 
from experiments in which transfection efficiency was greater than 55%.  
 
co-Immunoprecipitation and Western Blot 
 
MCF7 cells, transfected or not with LSDwt and mutant, were lysed with 
Lysis Buffer containing Tris-HCl (50 mM), EDTA (1mM), TRITON (1%), 
NaCl (150 mM), MgCl2 (5mM), EGTA (1mM), 1x protease inhibitor, 1x 
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PMSF and 1x Na3VO4.  Lysates, clarified by centrifugation at 12000g for 30’ at 
4°C, were co-immunoprecipitated with antibodies against LSD1 (sc-67272), 
FLAG tag M1 (A-4596) or normal IgG (as control), 1µg of antibody each mg 
of total proteins, accordingly to the specific experimental needs. In the former 
case, the anti-LSD1 co-immunoprecipitation was performed in Lysis Buffer, 
while in the latter case, anti-FLAG tag co-immunoprecipitation, 1mM CaCl2 
was added to the same Buffer. The sample were separated by SDS-PAGE and 
subjected to western blot. The nitrocellulose membranes were immunoblotted 
with antibodies against LSD1, P-(Ser/Thr)PKA substrate, P-CREB, GAPDH, 
PKA, RPA, RNA Pol II, NCoR1, H1 at the dilution of 1:1000 in 3% BSA in T-
TBS (0,1% tween in TBS) over night and antibodies against ER-α at the 
dilution of 1:5000 in 3% milk in T-TBS. Antibodies for the detection of ERα 
(sc-543 and sc-8005), PKA (sc-903), P-CREB (sc-101663), GAPDH (sc-
59540), H1 (sc-393358), and LSD1 (sc-271720) were purchased from Santa 
Cruz Biotechnology; RNA polymerase II antibody (05623) was obtained from 
Upstate Biotechnology; RPA antibody (A303-874A) was from Bethyl 
Laboratories; anti-flag antibody (F-3136) was from Sigma Aldrich; P-(Ser/Thr) 
PKA subustrate antibody was from Cell-Signaling Technology (9621); finally 
fluorescein isothiocyanate anti-rabbit and texas red anti-mouse were from 
Jackson ImmunoResearch Laboratories, Inc (UK). Image analysis for all gels 
was performed with ImageJ software using the "Gel Plot" plug-in. 
 
GST-ERα  fusion proteins preparation 
 
The DH5α bacteria cells expressing the following recombinant GST-ERα 
fusion proteins, GST-ERα wild type (Heg0); GST-ERα deleted of 1-280 
amino acids (Heg14); GST-ERα deleted of 281-595 amino acids (Heg15); 
GST-ERα deleted of 1-241 amino acids (Heg241-595) (Abbondanza C. et al. 
1998), were grown over night at 37°C. The day after each culture was diluted 
1:10 and grown until OD 0.5595nm, then 1mM IPTG was added to induce the 
expression of the recombinant proteins for 2h (see Figure 10 B).  
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Cells were lysed through freeze and thaw technique for three times in KCl 
15mM; PBS 1x; N-laurosylsarcosine 1.5%; Triton 0.5%; DTT 5mM; PMSF 
1mM; 1x proteases inhibitor. The lysates, purified by centrifugation for 10’ at 
14000g at 4°C, were incubated with Sefarose beads for 2h at 4°C. The GST-
ERα fusion proteins, collected by centrifugation at 1700g for 2’, were washed 
four times with PBS 1x. To test the fusion, the recombinant fusion proteins 
were subjected to SDS-PAGE and stained with Comassie blue. 
 
Pull-down assay. 
 
MCF7 Cells were lysed as above described. The cell extracts (2mg) were 
incubated, for 2h at 4°C with gentle rock agitation, with 2 µg of GST-Heg0, 
GST-Heg14, GST-Heg15, GST-Heg241 constructs respectively, in the 
presence or in the absence of 10nM estradiol. The pellets were washed in lyses 
buffer twice, and once in the lysis buffer with 200 mM NaCl and then 
processed for Western blot analysis as above described. 
 
Confocal microscopy of ERα-LSD1. 
 
MCF-7 cells, grown on glass slides, were hormone starved for 3 days, 
treated with E2 for the indicated times. Cells on coverslips were washed once 
with PBS, fixed for 20 min with paraformaldehyde (3%, w/v in PBS), 
permeabilized for 20 minutes with Triton X-100 (0.2%, v/v in PBS) and 
incubated for 1 h with PBS containing FCS (1%, v/v). For ER-α detection, 
coverslips were stained by incubation with anti-ER-α antibody diluted 1:100 in 
PBS for 1 h followed by three washings with PBS. Coverslips were then 
incubated in fluorescein isothiocyanate anti-rabbit (Jackson ImmunoResearch 
Laboratories, Inc, UK) diluted 1:200 in PBS. For LSD-1 detection, coverslips 
were stained by incubation with anti-LSD1 antibody diluted 1:100 in PBS for 1 
h followed by three washings with PBS. Coverslips were then incubated in 
texas red anti-mouse (Jackson ImmunoResearch Laboratories, Inc, UK) diluted 
1:200 in PBS. All coverslips were washed three times in PBS, incubated for 10 
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min with PBS containing Hoechst 33258 (Sigma) at a final concentration of 1 
mg/ml and finally washed three times with PBS. The coverslips were inverted 
and mounted in Moviol (Calbiochem, CA) on glass slides. All images were 
captured with Zeiss confocal microscope 510. The microphotographs were 
analyzed with ImageJ software using the colocalization and colocalization 
finder plug-insand the Pearson’s coefficient was calculated for each 
experimental point. 
 
In vitro kinase assay  
 
For LSD1 in vitro kinase assay, MCF7 cells transfected with pLSD1wt 
and pLSD1-Ala, were lysated with Lysis Buffer and lysates were incubated 
with anti-FLAG antibodies (Sigma A4596) in the presence of 1mM CaCl2 for 
2h at 4°C. Beads were washed two times with lysis buffer and then with kinase 
buffer (Hepes 50mM, MgCl2 1mM, DTT 1mM). For each sample the reaction 
was carried out in 50μl of kinase reaction mixture containing or not 50ng of 
PKA catalytic subunit (P2645, Sigma) and 25μM ATP with γP32-ATP 
(3mCi/mM), in the presence or in the absence of 1μM PKI (P0300, Sigma), and 
in the presence or in the absence of 25μM PKC inhibitor (476480 
Calbiochem). After 5 minutes of incubation at 30°C, the immunoprecipitated 
proteins were eluited first with a buffer containing 2mM EDTA, 400mM 
NaCl2, 200mM Tris-HCl pH 7.4, and then with glycine 0,1M pH 3. After that, 
sample buffer (2x) was added to the eluates followed by boiling for 5 min. The 
samples were subjected to SDS-PAGE and Western-Blot and finally the 
nitrocellulose membrane were exposed to light sensitive film.  
 
RNA isolation and qRT-PCR. 
 
Total RNA, from MCF7 cells transfected with LSD1wt and mutant, was 
extracted using TRIzol Reagent (Gibco/Invitrogen) following the 
manufacturer’s instructions. cDNA was prepared from 1µg of total RNA with 
100 U of Superscript III Reverse Transcriptase (Invitrogen) and 2 µl random 
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hexamer (20 ng/µl) (Invitrogen), the reverse-transcribed was carried out for 1 h 
at 50 °C, and the reaction was heat inactivated for 15 min at 70 °C. The cDNA 
products were stored at -20 °C until use. Each sample was assayed in triplicate. 
Quantitative reverse Transcription Polymerase Chain Reaction (qRT-
PCR) and Quantitative Polymerase Chain Reaction (qPCR) were performed 
three times in six replicates on a 7500 Real Time PCR System (Applied 
Biosystems) using the SYBR Green-detection system (FS Universal SYBR 
Green MasterRox/Roche Applied Science). All reactions were normalized to 
18S mRNA. The complete list of oligonucleotides used is reported in Table-1. 
 
Chromatin immunoprecipitation 
 
2.5 x 106 cells for each antibody, transfected and/or treated as indicated 
in the legends of the figures, were fixed with 1% formaldehyde for 10 minutes 
at room temperature. The reaction was quenched by the addition of glycine to a 
final concentration of 125 mM. Fixed cells were harvested and the pellet was 
resuspended in 1 ml of Lysis Buffer (10 mM Tris-HCl pH 8.0, 10 mM NaCl, 
0.2 % NP40) containing 1X protease inhibitor cocktail (Roche Applied 
Science). The lysates were sonicated in order to have DNA fragments from 300 
to 600 bp. Sonicated samples were centrifuged and supernatants diluted 2 fold 
in the ChIP Buffer (1% Triton X-100, 2 mM EDTA, 150 mM NaCl, 20 mM 
Tris-HCl pH 8.0). An aliquot (1/10) of sheared chromatin was further treated 
with proteinase K (4U every 1 x 106 nuclei), extracted with 1 volume of 
phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated in LiCl 0,4 M/ 
ethanol 75% to determine DNA concentration and shearing efficiency (input 
DNA). The ChIP reaction was set up according to the manufacturer’s 
instructions. Briefly, the sheared chromatin was precleared for 2 h with 1 μg of 
non-immune IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 20 μl 
of Protein A/G PLUS-Agarose (Santa Cruz Biotechnology) saturated with 
salmon sperm (1 mg/ml). Precleared chromatin was divided in aliquots and 
incubated at 4 °C for 16 h with 1 μg of the specific antibody (anti-FLAG M1 
and anti-H3K9me2) and non-immune IgG respectively. The immuno-
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complexes were recovered by incubation for 3 h at 4°C with 20 μl of protein-
A/G PLUS agarose, beads were washed with wash buffers according to the 
manufacturer’s instructions and immunoprecipitated DNA was recovered 
through phenol/chloroform/isoamyl alcohol extraction and ethanol 
precipitation and redissolved in TE buffer (10 mM Tris-HCl, 1mM EDTA, pH 
8,0). Samples were subjected to qPCR using the primers indicated in the legend 
of the specific figures, primers sequences are reported in Table 1. Real Time-
qPCRs were performed using FastStart Universal SYBR Green Master (Rox) 
(Roche Applied Science) with cycle conditions as follows: 
Caveolina 1 ERE: 95 °C 10’; 5x (95 °C 45’’, 65 °C 30’’, 72 °C 30’’); 
40x (95 °C 45’’, 62 °C 30’’, 72 °C 30’’); 72 °C 10 min. 
TSHR exone 10: 95 °C 10’; 40x (95 °C 45’’, 52 °C 30’’, 72 °C 35’’); 
72 °C 10 min. 
 
 Data analysis. 
 
All data are presented as mean ± standard error of at least three 
experiments in triplicate (n≥9). Differences between treatments were tested for 
statistical significance using Student’s matched pairs t test. Statistical analysis 
was performed using the JMP 6.0.3 software (SAS Institute Inc., USA - 
http://www.sas.com).   
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Table	  1	  	  
 PRIMERS for mRNA  
locus sequence   
pS2 5'-CCCTCCCAGTGTGCAAATA-3' Fw 
  5'-GATCCCTGCAGAAGTGTCTAAAA-3 Rev 
BCL2 5'-AGTACCTGAACCGGCACCT-3' Fw 
  5'-GGCCGTACAGTTCCACAAA-3' Rev 
Cav1 5'-AAACGTTCTCACTCGCTCTC-3' Fw 
  5'-CAAAGGTTTGTTCTGCTCGC-3' Rev 
S100p 5'-GGGAGCTCAAGGTGCTGAT-3' Fw 
  5'-AGCAATTTATCCACGGCATC-3' Rev 
18S 5’-TCCCCATGAACGAGGAATTC-3’  Fw 
  5’-GGCCTCACTAAACCATCCAA-3’  Rev 
      
  PRIMERS for ChIP   
locus sequence   
Cav1- ERE 5’-TAAAGCTGGAAGGGATTACCG-’3 Fw 
  5’-CTTCTCCCGGACTCCCTAAG-’3 Rev 
TSHR-Ex 10 5’-ACCGAGACCCCTCTTGCTCT-3’ Fw 
  5’-AGTTGCTAACAGTGATGAGAGGCT-3’ Rev 	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Results 
 
Estrogens and cAMP-PKA stimulate the formation of the complex: 
LSD1, the estrogen receptor α and RNA Polymerase II.  
 
Estrogens, in addition to canonical genomic pathway, activate several 
non-canonical transduction systems (Beato M. et al., 1989; Kelly M. J. and 
Levin E. R., 2001). Estrogen has been shown to activate cAMP-PKA signaling 
that cooperates by propagating the estrogen signals to several cellular 
cytoplasmic and nuclear effectors (Aronica S. M. et al, 1994). PKA has been 
involved in ERα-mediated rapid effects in many different processes. For 
example, in the basal forebrain cholinergic neurons in vivo PKA inhibition 
reduces the estrogen-induced CREB phosphorylation (Szego E’va M. et al., 
2006). PKA inhibition reduces estrogen induction of breast cancer cell 
proliferation (Houslay M. D. and Kolch W., 2000) and the transcription 
activation (Liu D. et al., 2009). 
To confirm that estrogens induce the cAMP-PKA pathway in our 
cellular model, MCF-7 cells were pretreated or not with H89, a permeable 
PKA inhibitor, and stimulated for 5’ and 30’ with E2 or for 15’ with Forskolin, 
a cell-permeable adenylate cyclase activator. Total cell extracts were resolved 
on SDS-PAGE and blotted with antibodies against anti-P (Ser/Thr) PKA 
substrate to detect bands corresponding to substrates phosphorylated by PKA. 
We find that E2 is able to rapidly induce (5’) phosphorylation of many PKA 
substrates, (Figure 9A and B) and that prolonged exposure to E2 (30’) does not 
increase the number of the bands, suggesting the effect of E2 on cAMP-PKA 
signal is rapid and transient. Inhibition of PKA with H89 affects this early 
PKA-dependent phosphorylation reducing and delaying the phosphorylation 
profile at 30’ of E2 stimulation (Figure 9, compare lane 3 to 6). Furthermore, 
the phosphorylation of CREB, a well-known PKA substrate, confirms that E2 
induces the activation of PKA pathway in our cellular model. Forskolin 
induces the same pattern of phosphorylated bands seen with E2 (Figure 9, lane 
8).  
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Although many studies have pointed out the importance of LSD1 
during carcinogenesis or development (Rotili D. and Mai A. 2011; Shi Y. et al., 
2005; Lynch J.T. et al., 2012; Cohen I. et al., 2011), its role in regulating gene 
expression is emerging only recently. LSD1 is involved as co-repressor in 
several molecular complexes, including CoREST and NuRD and as co-
activator in androgen or estrogen receptors (Shi Y. et al., 2003; Perillo B. et al., 
2008). Consistent with its role in transcriptional repression, LSD1 
demethylates mono-methyl and di-methyl histone H3 lysine 4 (H3K4me1 and 
H3K4me2), which mark active chromatin. Nevertheless, the precise 
mechanism of activation of the enzyme in vivo remains still elusive.  
To dissect the mechanism of LSD1 activation/recruitment to 
ERE/chromatin by E2, we performed immunoprecipitation experiments in 
protein extracts from MCF-7 cells exposed to E2 and/or cAMP. To this end, 
MCF-7 cells were starved from the hormone with 10% Charcoal Stripped 
Serum (CSS) for 3 days and exposed to E2 and/or cAMP in the presence and in 
the absence of the classical anti-estrogen or anti–PKA drugs, ICI-18278 and/or 
H89, respectively. To detect the proteins interacting with LSD1 during the 
estrogen-stimulation, total protein extract was immunoprecipitated with anti-
LSD1 antibody and tested for the presence of the estrogen receptor alpha 
(ERα) and the RNA polymerase II (RNA Pol II) by immunoblotting. Figures 9 
C and D show that the binding of LSD1 to the ERα and to RNA Pol II is 
stimulated by E2 and cAMP and prevented by H89 and ICI-18278. The 
simultaneous treatment with cAMP and E2 does not improve the efficiency of 
binding compared to single treatments, suggesting that the two pathways are 
not synergic. Moreover, ICI and H89 prevent the interaction of LSD1 with 
ERα and RNA Pol II, induced by E2 and cAMP (Figure 9C and D). These data 
demonstrate that the binding of LSD1 to ER-α and RNA Pol II occurs via 
cAMP/PKA pathway stimulated by E2. 
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LSD1 interacts with the N-terminal domain of ERα and co-localizes 
in the nucleus after estrogen stimulation. 
 
To determine which domain of the estrogen receptor is involved in the 
interaction with LSD1, we have performed an “in vitro” pull-down assay 
(Figure 10A) using different GST-ER fusion proteins (see material and 
methods and Figure 10B, upper panel). MCF-7 cell extracts were incubated for 
3h at 4°C in the presence or in the absence of E2 with different Sepharose-
bound GST-ER fusion proteins and then subjected to western blot analysis with 
anti-LSD1 antibodies. We find that LSD1 binds only the ERα recombinant 
proteins that contain the N-terminus fragment (Heg0, Heg15), indicating that 
LSD1 does not interact with C-terminal domain of ERα. The interaction with 
the full-length receptor form is dependent on estrogens; in contrast, Heg15-
LSD1 interaction is not induced by estrogen, because this protein does not 
contain E2 binding domain (Figure 10B, lower panel).  
To visualize the cellular compartment where the formation of ERα-
LSD1 complex occurs, we have stained MCF-7 cells, treated for 15’, 30’, 45’ 
with E2, with anti-LSD1 and anti-ERα antibodies and analyzed the localization 
of the proteins by confocal microscopy. We find that LSD1 is essentially 
localized in the nucleus and this localization is stimulated by exposure to E2. In 
particular, between 15 and 30 min, the two signals (LSD1, red; ERα, green) 
increase and overlap, indicating that upon E2 stimulation, the receptor rapidly 
accumulates into nucleus, where it binds and targets LSD1 to the estrogen-
specific sites of chromatin (Figure 10C). 
Collectively, these data indicate that LSD1 is able to bind ERα in the nucleus  
both “in vivo” and “in vitro” in estrogen-dependent manner. 
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LSD1 Threonine	  110 is a specific PKA phosphorylation target both 
“in vivo” and “in vitro”. 
 
Recently, many research groups focused their attention on the role of 
different phosphorylation sites in the N-terminal region of LSD1 and their 
involvement in the regulation of histone methylation. Costa R. et al. have 
found Ser131, Ser137 and Ser166 residues in LSD1 as new substrates of 
protein kinase CK2 and demonstrate that the phosphorylation of these sites 
modulate the interaction with partners involved in formation of repression and 
activation complexes (Costa R. et al., 2014). Moreover, several data suggest 
that the LSD1 is a target of PKA. Perillo et al. demonstrated that LSD1 
recruitment to BCL-2 ERE site is stimulated by cAMP-PKA, because H89 
prevents the H3K9me2 demethylation and the recruitment of LSD1 to BCL-2 
chromatin in E2-stimulated cells (Perillo B. et al., 2013). In addition, a LSD1 
threonine mutant (T110A) inhibits cAMP and Myc-induced gene expression 
compared to the LSD1 wild type (Amente S. et al., 2011). However, to date the 
direct proof that T110 in LSD1 is a PKA site is lacking. Here we demonstrate 
that LSD1-T 110 is a specific target of PKA by performing experiments in vivo 
and in vitro”.  
First, we co-transfected MCF-7 cells with an expression vector 
encoding tagged (FLAG)-LSD1 variants: the wild type and a mutant in T110 
(LSD1-Ala) in the presence and in the absence of pRSV-PKI that expresses the 
synthetic protein kinase inhibitor peptide (Day R. N. et al., 1989). Transfected 
cells were hormone starved and treated with E2. Total proteins were extracted 
and immunoprecipitated with anti-FLAG antibodies. LSD1 phosphorylation 
was assayed by Western blot analysis with antibodies against the 
phosphorylated Ser/ Thr PKA substrates. A specific PKA phosphorylated 
protein band migrating with an apparent M.W. of 100 KDa was visible only in 
the immunoprecipitates from MCF-7 cells transfected with LSD1wt and 
stimulated with estrogens, indicating that estrogens induce PKA-dependent 
phosphorylation of LSD1 (Figure 11A).  
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To confirm that LSD1 is directly phosphorylated by cAMP-PKA, the 
expressed protein was submitted to an “in vitro” phosphorylation assay. To this 
end, LSD-wt and 
LSD-Ala were 
expressed in MCF-7 
and the relative 
proteins were purified 
by immune-
precipitation with 
anti-FLAG 
antibodies, eluted and 
incubated “in vitro” 
with the purified 
catalytic subunit of 
PKA and γ-P32-ATP, 
with or without the 
specific PKA 
inhibitor, PKI, and in 
the absence or in 
presence of a PKC 
inhibitor (PKCi) to 
test the kinase specificity. Figure 11B shows that LSD1wt is phosphorylated by 
PKA, because the phosphorylation is significantly reduced by PKI. However, 
the mutated protein also in the presence of PKI shows a residual and significant 
phosphorylation. Differently from LSD1wt, the phosphorylation of LSD1ala is 
totally abrogated by PKCi. We conclude that PKC can also phosphorylate 
LSD1, but at another site and that Threonine 110 of LSD1 is a specific site 
phosphorylated by PKA.  
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Phosphorylation of LSD1 at Threonine 110 regulates its interaction 
with estrogen-induced initiation transcriptional complex. 
 
Since the alanine substitution in LSD1 does not affect the enzymatic 
activity of LSD1 (Zuchegna C. et al, 2014), we hypothesize that 
phosphorylation of T 110 residue modulates the interaction with different 
partners that regulates estrogen-dependent transcription. To test the binding 
ability of wild type and alanine mutant LSD1 with other nuclear proteins 
involved in E2-induced transcription, we probed the anti-FLAG 
immunoprecipitates with the antibodies targeting several proteins, as shown in 
Figure 4A. The data demonstrate that the treatment with E2 or cAMP induces 
the interaction between LSD1-wt and ER-α, RNA polymerase II, PKA 
catalytic sub-unit and the single strand binding protein, RPA. Under the same 
conditions, LSD1-Ala mutant weakly interacts with ER-α, RNA polymerase II, 
PKA catalytic subunit compared to the wild type form, and does not bind RPA. 
It is worth noting that LSD1-Ala binds more efficiently N-CoR and histone H1 
to than LSD1-wt upon E2 and cAMP treatments. These data suggest that LSD1 
mutant interacts with histone H1 and N-CoR, which are associated with 
compacted chromatin and repression of transcription, respectively, suggesting 
that non-phosporylated LSD1 acts as a negative dominant regulator of 
estrogen-induced gene transcription (Figure 12 A&B). 
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LSD1-T110 phosphorylation is required for estrogen-dependent 
transcription. 
LSD1 mediates inter-chromosomal interactions necessary for estrogen-
dependent transcription (Hu Q. et al., 2008). In particular, the physical 
presence of LSD1 both as a scaffolding protein, and as demethylase enzyme at 
the ERE region was important for ERα-regulated transcription. In fact E2 
treatment induces the recruitment of ERα and LSD1 to ERE of pS2, and 
influences the methylation status of histones at the pS2 ERE chromatin 
(Pollock Julie A. et al., 2012). To determine whether LSD1-Ala alters the 
methylation of H3K9 or H3K4me2 and to find out the consequences on 
transcription induced by estrogens, chromatin immunoprecipitation assay and 
gene-expression analysis were performed in cells exposed to E2. Figures 13A 
and B show that LSD1 wild type is recruited to the ERE upon estrogen 
challenge. The recruitment of wild type LSD1 to the ERE-containing 
chromatin is associated with a strong reduction of H3K9me2 levels (Figures 
13A and B). LSD1-Ala, on the other hand, is present at several chromatin 
regions, but its recruitment is not stimulated by estrogens. Over-expression 
LSD1-Ala is associated with reduction of basal H3K9me2 levels, which are not 
dependent on estrogens (Figures 13 A and B). Lower H3K9me2 levels are non 
specific of chromatin containing ERE consensus, since other sites, non induced 
by estrogens, display reduced levels of H3K9me2, indicating that LSD1 is 
recruited to chromatin by other factors (Figure 13B). To determine the 
consequences of LSD1-Ala expression on estrogen-induced transcription, we 
have analyzed the expression of several genes (pS2 or TFF1, BCL-2, CAV1 
and S100p) induced by estrogens in cells expressing LSD1-Ala. Figure 13C 
shows that the LSD1-Ala mutant significantly inhibits estrogen-induced 
transcription of all genes analyzed. We notice that LSD1-Ala also, increased 
the basal transcription, hormone-independent, of some estrogens-induced 
genes, such as pS2 and S100p, indicating that LSD1-Ala renders the expression 
of these genes constitutive and estrogen independent.  
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cAMP and Estrogens cooperate at multiple levels to stimulate 
transcription. 
PKA cooperates with many transduction pathways. The cooperation with 
estrogens is not confined to the nucleus, but it is also operating in the 
membrane-cytosolic compartments, where cAMP-PKA amplify estrogen 
induction of PI3K (Cosentino C. et al., 2007). The major estrogen receptor 
anchor protein in the membrane-cytoplasmic compartments is p85-PI3K, while 
in the nucleus the receptor is mainly associated with LSD1 (Figure 10C). Both 
p85-PI3K and LSD1 bind the E2 receptor only when they are phosphorylated 
by PKA at specific sites (Cosentino C. et al., 2007 and Figure 12). Inhibition of 
cAMP-PKA signaling severely impairs genomic and non-genomic estrogen 
signaling and recent evidence indicates that sustained PKA activation leads to 
phosphorylation and binding of the receptor to a coactivator associated arginine 
methyl transferase, but is not able alone, to activate ERα (Carascossa S. et al., 
2010). LSD1, bound to the receptor complex, is tightly dependent on ligated 
receptor and may sense nuclear PKA oscillations to finely tune nuclear 
responses to estrogen passage from the cytoplasm to the nucleus. 
LSD1 as repressor and activator of transcription 
 LSD1 is also a repressor of transcription, because it has been found associated 
to Rb and p53 in a cell cycle dependent manner (Chau C. M. et al., 2008; 
Huang J. et al., 2007), to repress telomerase reverse transcriptase (hTert) 
expression (Zhu Q. et al., 2008), and to induce and maintain the silenced state 
of the zinc finger transcription factor Snail1 target genes in invasive cancer 
cells. (Lin T. et al., 2010). LSD1 has been initially isolated as repressor of 
transcription, mainly because it erases the activation mark H3K4me2 (Shi Y. et 
al., 2004). However, there is evidence that LSD1 can also activate transcription 
by removing the repressor mark H3-K9me2 (Perillo B. et al., 2008). The mono 
aminoxidase activity of LSD1 is essential both for transcription activation 
induced by androgens, estrogens and Myc and transcription repression. During 
these processes, LSD1 changes its demethylating activity from H3K4me2 to 
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H3K9me2, favoring the demethylation of H3K9me2 “in vivo” (Metzger E. et 
al., 2005; Perillo B. et al. 2008; Amente S. et al., 2010).  One interesting 
hypothesis that combines these apparent contradictory results is the following: 
many genes contain at the transcription start site nucleosomes carrying 
negative (H3K9me2) and positive (H3K4me2) marks. These genes are poised 
in an intermediate state, since they can be activated or inhibited depending on 
the stimulus. LSD1 can mediate both effects in dependence on the type of 
activator; removal of H3K4me2 leads to repression, whereas, removal of 
H3K9me2 activates transcription. 
 LSD1 forms a platform for the assembly of the transcription initiation 
complex 
The data presented here show that LSD1 recruits multiple components of the 
transcription initiation complex. The binding of LSD1 to ER-α and the RNA 
Polymerase II is induced by estrogens and requires a short cAMP-PKA signal. 
This is shown by the experiments with ICI. ICI interferes with the estrogen 
receptor shuttling from the cytoplasm to the nucleus, preventing the access of 
activated receptors to the chromatin. Treatment with this anti-estrogen 
molecule prevents the interaction of estrogen receptor with LSD1 and many 
nuclear components. The same process is also inhibited by H89, indicating that 
cAMP and PKA are essential to complete the assembly of the transcription 
initiation complex. The very rapid PKA induction (5’) shows the convergence 
on LSD1 of the early nuclear and cytoplasmic signaling of estrogens and 
cAMP.  
We suggest that PKA serves as a general nutrient sensing mechanism that 
amplifies the action of many transcription factors and LSD1 represents the 
structural and enzymatic platform (achieved by demethylating histone H3K9 or 
K4 and DNA oxidation) that assembles the transcription initiation complex. 
As to the specific mechanism governing the ordered assembly of the 
initiation complex, our data indicate that phosphorylation at threonine 110 of 
LSD1 influences the choice of the chromatin partners. For example, LSD1-Ala 
binds H1 and NCoR, not RNA polymerase II and this complex mediates the 
repression of transcription in the absence of PKA and estrogens. 
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In conclusion, we propose that the choice of partners by LSD1 is dependent 
on the phosphorylation of threonine 110 induced by cAMP-PKA and this 
represents a simple and elegant strategy linking estrogen signaling to 
metabolism and nutrient sensing.  
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